SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkmate Pharmaceuticals, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - April 20, 2022) - Rigrodsky Law, P.A. is investigating Checkmate Pharmaceuticals, Inc. ("Checkmate") (NASDAQ: CMPI) regarding possible breaches of fiduciary duties and other violations of law related to Checkmate's agreement to be acquired by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Under the terms of the agreement, Checkmate's shareholders will receive $10.50 in cash for each share of Checkmate common stock they own.
To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-checkmate-pharmaceuticals-inc.
To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email email@example.com.
Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.
Rigrodsky Law, P.A.
Seth D. Rigrodsky, Esq.
Gina M. Serra, Esq.
Call or Text: (302) 295-5310
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/121014